Smith & Nephew Presents Excellent Results for JOURNEY™ II Total Knee at the 2018 American Association of Hip and Knee Surgeons

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, presented a number of compelling clinical outcomes around its flagship JOURNEY II BCS knee earlier this month at the American Association of Hip and Knee Surgeons (AAHKS). The announcement follows more than a dozen publications during the past year from various authors around the globe.^1-14

In one of the largest multi-center retrospective patient cohorts ever studied, new clinical evidence represented excellent mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants including:

• About 1% of patients required major revision out to 6 years.¹⁵
• No major or minor revision of any patient four years or more post-op.¹⁵
• Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).¹⁵
• Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at 6 years. The revision rate was 3% at 5 years for males and 3.1% for females, compared to 7% for males and 6.9% for females reported by the AOANJRR for cemented PS TKAs.¹⁵

These data add to the growing body of evidence that JOURNEY II TKA delivers smoother patient recovery, improved functional outcomes, higher patient satisfaction and healthcare cost-savings when compared with conventional TKAs. ^{1,2,6,7,9,16,17}

“It is very exciting to see additional clinical validation in such a large study showing excellent patient outcomes with our JOURNEY II TKA.  For years we at Smith & Nephew have been discussing the unique benefits of JOURNEY II knees and we are now seeing regular publications highlighting the improved outcomes compared to conventional TKAs.  These better-quality outcomes are a direct benefit to our surgeon customers and most importantly to their patients,” said Skip Kiil, President of Global Orthopaedics, Smith & Nephew.

JOURNEY II TKA first launched in late 2011 and now has more than 150,000 procedures performed worldwide.¹⁸

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew plc 

Charles Reynolds
+44 (0) 1923 477314
Smith & Nephew plc

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twittervisit SmithNephewplc on Facebook.com.

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.}

^{◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.}